Article Text

Drug improves survival in dobermanns with preclinical dilated cardiomyopathy

Statistics from

THE results of an international study have suggested that there is a clear survival benefit associated with the administration of the drug pimobendan in the preclinical phase of cases of dilated cardiomyopathy (DCM) in dobermanns.

A paper published online in the Journal of Veterinary Internal Medicine this month describes how the global PROTECT study, carried out between 2006 and 2011, found that when pimobendan (Vetmedin; Boehringer Ingelheim Animal Health) was administered to dobermanns with preclinical DCM, the onset of heart failure or sudden …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.